Zhen Su
Company: Marengo Therapeutics
Job title: Chief Executive Officer
Seminars:
Surging Ahead with the Next Wave of Precision Immuno-Oncology to Unleash the Power of T-cell Immunity 9:25 am
TCR-targeted therapies utilize engineered T-cell receptors to precisely recognize a variety of cancer antigens presented on cell surface via MHC molecules, allowing for targeted attack against a broad range of cancers at their core These therapies offer increased specificity by targeting intracellular antigens, potentially addressing tumor heterogeneity and providing a more comprehensive approach compared to…Read more
day: Conference Day One
Chair’s Opening Remarks 7:50 am
day: Conference Day One